Search results
Results from the WOW.Com Content Network
The FDA is reversing course on its COVID vaccine guidance: Rather than having a vaccine that targets the older JN.1 variant, the FDA said fall 2024 vaccines should target a newer strain of the virus.
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
In June 2021, the initial EUA status of the vaccines led to challenges as to whether such mandates were legal, [17] as FDA regulations state that a person must be informed "of the option to accept or refuse administration of the product, of the consequences, if any, of refusing administration of the product, and of the alternatives to the ...
A packet of AstraZeneca COVID-19 vaccine vials. A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, [1] and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol.
The FDA plans to decide on what’s next for COVID-19 vaccines after receiving recommendations on a “fall strain” vaccine composition in June at an advisory committee meeting, the agency said.
A spokesperson for the FDA said the agency can’t comment on timing of product applications but noted that it “anticipates taking timely action to authorize or approve updated COVID-19 vaccines ...
A study on the effectiveness of a first dose of the Pfizer–BioNTech or Oxford–AstraZeneca COVID-19 vaccines against COVID-19 related hospitalisation in Scotland was based on a national prospective cohort study of 5.4 million people. Between 8 December 2020 and 15 February 2021, 1,137,775 participants were vaccinated in the study, 490,000 of ...
The US Food and Drug Administration on Tuesday authorized Novavax’s updated protein-based Covid-19 vaccine for people 12 and older.